A Comparison of Radiation and Alkylator-Based Conditioning Therapy Regimens for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Clinician’s Perspective

TL;DR

This paper compares different conditioning therapies for stem cell transplants in acute myeloid leukemia, focusing on balancing effectiveness and toxicity.

Contribution

The paper provides a clinician's perspective on emerging conditioning strategies that aim to reduce toxicity while maintaining effectiveness in stem cell transplantation.

Findings

Myeloablative regimens reduce relapse but increase toxicity and non-relapse mortality.

Reduced-intensity regimens are less toxic but may lead to higher relapse rates.

Emerging strategies aim to balance toxicity reduction with improved survival outcomes.

Abstract

In this article, we discuss different conditioning regimes used for stem cell transplantation in acute myeloid leukemia. Conditioning allows for the reduction of the leukemic burden and prepares the body for the donor’s stem cells. Myeloablative regimens lower relapse chances but come with a higher risk of side effects. Reduced-intensity regimens are less toxic but may result in increased rates of relapse. Identifying conditioning regimens that result in low toxicity but are effective is an area of research interest in the stem cell transplant field. We give an overview of commonly employed conditioning strategies and comment on emerging strategies.

Hematopoietic stem cell transplantation (HSCT) remains the only curative treatment option for most patients with acute myeloid leukemia. Optimizing the conditioning regimen is critical in HSCT planning. Myeloablative conditioning regimens have been shown to reduce relapse but often lead to increased toxicity and non-relapse mortality. In contrast, reduced-intensity conditioning offers a less toxic alternative, though it has been associated with a higher risk of relapse. Emerging conditioning strategies provide a promising balance between reducing toxicity and improving survival outcomes. In this paper, we summarize current available data related to conditioning regimens for patients with AML undergoing HSCT, highlighting novel findings and focusing on emerging modalities.

Figures